No data to show
OTCM
STME
Market cap142mUSD
Jun 09, Last price
0.48USD
Name
Cell MedX Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
29.46%
Rev. gr., 5y
25.74%
Revenues
0k
-100.00%
Net income
-142k
L-71.22%
CFO
-146k
L-46.40%
Earnings
Aug 27, 2025
Profile
Cell MedX Corp., a biotech company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is based in Carson City, Nevada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑05 | 2023‑05 | 2022‑05 | 2021‑05 | 2020‑05 | 2019‑05 | 2018‑05 | 2017‑05 | 2016‑05 | |
| Income | |||||||||
Revenues | 3 -54.46% | ||||||||
Cost of revenue | 313 | 450 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (313) | (448) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (170) | ||||||||
Tax Rate | |||||||||
NOPAT | (313) | (277) | |||||||
Net income | (142) -71.22% | (495) -31.54% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 75 | ||||||||
BB yield | -1.04% | ||||||||
| Debt | |||||||||
Debt current | 313 | 1,001 | |||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 270 | 903 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (146) | (272) | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 91 | 346 | |||||||
FCF | (1,185) | (285) | |||||||
| Balance | |||||||||
Cash | 43 | 98 | |||||||
Long term investments | |||||||||
Excess cash | 43 | 98 | |||||||
Stockholders' equity | (9,563) | (9,658) | |||||||
Invested Capital | 9,050 | 8,274 | |||||||
ROIC | |||||||||
ROCE | 61.10% | 32.33% | |||||||
| EV | |||||||||
Common stock shares outstanding | 161,008 | 62,923 | |||||||
Price | 0.05 44,900.00% | 0.00 -99.90% | |||||||
Market cap | 7,245 115,046.65% | 6 -99.90% | |||||||
EV | 7,515 | 909 | |||||||
EBITDA | (313) | (448) | |||||||
EV/EBITDA | |||||||||
Interest | 47 | ||||||||
Interest/NOPBT | |||||||||